Clinical Trial Update: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the combination of BKM-120 (buparlisib) and fulvestrant in postmenopausal patients with estrogen receptor-positive stage IV breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• BKM-120 (buparlisib) (buparlisib)
• Faslodex (fulvestrant)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer | Phase 1 | Status: COMPLETED